Palvella Therapeutics (PVLA) Stock Analysis

What Palvella Therapeutics does

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Key metrics

ETFs linked to PVLA

Broad-market and Healthcare sector ETFs an investor holding Palvella Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PVLA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Palvella Therapeutics?

Palvella Therapeutics trades under the ticker PVLA on NASDAQ.

Which exchange is PVLA listed on?

PVLA is listed on NASDAQ.

What sector does Palvella Therapeutics operate in?

Palvella Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PVLA in a portfolio?

PortView shows PVLA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.